BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Anadys Pharmaceuticals, Inc. (ANDS) in Connection with the Sale of the Company to Roche Holding AG (RHHBF.PK)


10/17/2011 1:49:30 PM

NEW YORK, Oct. 17, 2011 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Anadys Pharmaceuticals Inc. ("Anadys" or the "Company") (NASDAQ: ANDS) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Roche Holding AG. Under the terms of the transaction, Anadys shareholders will receive $3.70 in cash per share of Anadys stock they own. The transaction is valued at approximately $230 million.

Click here to learn more about the investigation: http://zlk.9nl.com/anadys-pharmaceuticals/, or call: 877-363-5972.

The investigation concerns whether the Anadys Board of Directors breached their fiduciary duties to Anadys stockholders by failing to adequately shop the Company before entering into this transaction and whether Roche Holding AG is underpaying for Anadys shares, thus unlawfully harming Anadys stockholders. Roche has said that the proposed acquisition would boost its own portfolio of hepatitis C drugs, which include Pegasys and Copegus. While the deal is priced at $3.70 per share, at least one analyst has set a price target for the stock of $4.00 per share.

If you own common stock in Anadys and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com.

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major litigations involving mergers and acquisitions. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 15th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES